STATINS SLOW PROSTATE GROWTH: RESULTS FROM THE REDUCTION BY DUTASTERIDE OF CANCER EVENTS (REDUCE) TRIAL

被引：0
|
作者：
Muller, Roberto
Gerber, Leah
Moreira, Daniel
Andriole, Gerald
Parsons, J. Kellogg
Fleshner, Neil
Freedland, Stephen
机构：
来源：
JOURNAL OF UROLOGY | 2012年 / 187卷 / 04期
关键词：
D O I：
10.1016/j.juro.2012.02.1567
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
1249
引用
收藏
页码：E505 / E505
页数：1
相关论文
共 50 条
  • [41] SERUM TESTOSTERONE AND DIHYDROTESTOSTERONE AND INCIDENCE AND PROGRESSION OF LOWER URINARY TRACT SYMPTOMS IN REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS TRIAL
    Daniels, James
    Mirocha, James
    Moreira, Daniel
    Andriole, Gerald
    Freedland, Stephen
    [J]. JOURNAL OF UROLOGY, 2023, 209 : E71 - E71
  • [42] The REDUCE trial:: chemoprevention in prostate cancer using a dual 5α-reductase inhibitor, dutasteride
    Musquera, Mireia
    Fleshner, Neil E.
    Finelli, Antonio
    Zlotta, Alexandre R.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (07) : 1073 - 1079
  • [43] FURTHER ANALYSES FROM THE REDUCE PROSTATE CANCER RISK REDUCTION TRIAL
    Andriole, Gerald
    Bostwick, David
    Brawley, Otis
    Gomella, Leonard
    Marberger, Michael
    Montorsi, Francesco
    Pettaway, Curtis
    Tammela, Teuvo
    Teloken, Claudio
    Tindall, Donald
    Teloken, Claudio
    Tindall, Donald
    Somerville, Matthew
    Rittmaster, Roger
    [J]. JOURNAL OF UROLOGY, 2009, 181 (04): : 555 - 555
  • [44] Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial
    Wiggins, Emily K.
    Oyekunle, Taofik
    Howard, Lauren E.
    Markt, Sarah C.
    Mucci, Lorelei A.
    Bliwise, Donald L.
    Moreira, Daniel M.
    Andriole, Gerald L.
    Hopp, Martin L.
    Freedland, Stephen J.
    Allott, Emma H.
    [J]. PROSTATE, 2020, 80 (15): : 1304 - 1313
  • [45] PROSTATE CANCER A closer look at the initial results from the REDUCE trial
    Gann, Peter H.
    [J]. NATURE REVIEWS UROLOGY, 2010, 7 (10) : 535 - 537
  • [46] UTILITY OF COMBINING FINAL PSA AND PSA DYNAMICS (CHANGE FROM MONTH 6 TO FINAL PSA) FOR PROSTATE CANCER AND HIGH GRADE CANCER DIAGNOSIS IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) STUDY
    Andriole, Gerald L.
    Freedland, Stephen J.
    Tindall, Donald J.
    Tammela, Teuvo L. J.
    Teloken, Claudio
    Somerville, Matthew C.
    Wilson, Timothy H.
    Rittmaster, Roger S.
    [J]. JOURNAL OF UROLOGY, 2010, 183 (04): : E769 - E769
  • [47] DO METABOLIC COMORBIDITIES INFLUENCE THE ABILITY OF DUTASTERIDE TO LOWER PROSTATE CANCER RISK? RESULTS FROM THE REDUCE STUDY
    Freedland, Stephen
    Gerber, Leah
    Banez, Lionel L.
    McKeever, Madeline G.
    Moreira, Daniel M.
    Andriole, Gerald L.
    Rittmaster, Roger S.
    [J]. JOURNAL OF UROLOGY, 2011, 185 (04): : E483 - E483
  • [48] COST-EFFECTIVENESS OF DUTASTERIDE AS A CHEMOPREVENTION IN PROSTATE CANCER: REDUCE WITHIN-TRIAL ANALYSIS
    Earnshaw, S. R.
    Chirila, C.
    McDade, C.
    Black, L.
    Andriole, G. L.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A11 - A11
  • [49] COST-EFFECTIVENESS OF CHEMOPREVENTION WITH DUTASTERIDE BASED ON RESULTS FROM THE REDUCE CLINICAL TRIAL
    Earnshaw, S. R.
    McDade, C. L.
    Black, L.
    Kattan, M. W.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A271 - A271
  • [50] EFFECT OF BASELINE CHARACTERISTICS ON RELATIVE RISK OF PROSTATE CANCER PROGRESSION IN THE REDUCTION BY DUTASTERIDE OF CLINICAL PROGRESSION EVENTS IN EXPECTANT MANAGEMENT (REDEM) TRIAL
    Fleshner, N. E.
    Lucia, M. S.
    Egerdie, B.
    Black, L.
    Melich, K.
    Nandy, I
    Rittmaster, R.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 51 - 52
12345